NEW YORK--(BUSINESS WIRE)--ChipDX LLC, a New York-based molecular diagnostics and personalized medicine research company, has discovered a gene expression signature present in the cells of early-stage breast tumors that indicates the chance of the tumor recurring within 10 years. This genomic information was used to develop a prognostic test, BreastGeneDX, which ChipDX plans to have FDA-cleared for clinician access via an online analysis system. This personalized assessment of recurrence risk may assist in making informed decisions about monitoring and treatment options that are especially important for patients diagnosed with early-stage breast cancer.
